Literature DB >> 33907472

Attrition and Its Predictors Among Adults Receiving First-Line Antiretroviral Therapy in Woldia Town Public Health Facilities, Northeast Ethiopia: A Retrospective Cohort Study.

Demeke Dejen1, Dube Jara2, Fanos Yeshanew3, Zinabu Fentaw4, Tesfa Mengie Feleke5, Fentaw Girmaw6, Birhanu Wagaye3.   

Abstract

INTRODUCTION: There is an expansion and advancement of antiretroviral therapy. However, attrition of patients from HIV care is one of the major drivers of poor performance of HIV/AIDS programs, which leads to drug resistance, morbidity and mortality. The study aimed to assess the incidence of attrition and its predictors among adults receiving first-line antiretroviral therapy.
METHODS: An institution-based retrospective cohort study was conducted among 634 adults receiving antiretroviral therapy, and study participants were selected using a simple random sampling technique. Data were cleaned and entered into Epi Data version 3.1 and exported to STATA 14.1 for further analysis. The predictors of attrition were identified using bivariable and multivariable Cox Proportional hazard models; then, variables at a p-value of less than 0.25 and 0.05 were included in the multivariable analysis and statistically significant, respectively.
RESULTS: The total time observed was found to be 1807.08 person-years of observation with a median follow-up time of 2.67 years (IQR 1.25-4.67). The incidence rate of attrition was 8.36 (95% CI: 7.12-9.80) per 100 person-years. Significant predictors of attrition were being young age [adjusted hazard ratio (AHR) =2.0, 95% CI, (1.11-3.58)], nearest calendar year of ART initiation [AHR =2.32, 95% CI, (1.08-5.01)], bedridden functional status [AHR=3.25, 95% CI, (1.33-7.96)], WHO stage III [AHR=3.57, 95% CI, (1.58-8.06)] and stage IV [AHR=5.46, 95% CI, (1.97-15.13)], viral load result of ≤1000 [AHR=0.11, 95% CI, (0.06-0.23)], disclosure status [AHR=2.03, 95% CI, (1.22-3.37)] and adherence level of poor [AHR=3.19, 95 CI, (1.67-6.09)].
CONCLUSION: The result of this study showed that the incidence of attrition among adults receiving antiretroviral therapy was high. However, as a standard, every client who started antiretroviral therapy should be retained. Positive predictors of attrition were young age (15-24), recent year of ART initiation, baseline functional status, advanced WHO stage III and IV, no disclosure status, fair/poor adherence whereas, viral load result of ≤1000 copies/mL had a preventive effect on attrition.
© 2021 Dejen et al.

Entities:  

Keywords:  Ethiopia; HIV/AIDS; antiretroviral therapy; attrition; retrospective cohort

Year:  2021        PMID: 33907472      PMCID: PMC8068483          DOI: 10.2147/HIV.S304657

Source DB:  PubMed          Journal:  HIV AIDS (Auckl)        ISSN: 1179-1373


Introduction

Attrition is the contrary of retention on antiretroviral therapy (ART). It is the summation of the dead, lost to follow-up (LTFU), and stop from chronic ART care.1 On the contrary, retention in ART care is a continuous engagement of patients linked to HIV care, and it is one of the crucial indicators of the success of ART programs.2 Globally, over 37.9 million people were living with HIV/AIDS. Two-thirds of them were in Sub–Saharan Africa, and 24.5 million people on ART, 62% were adults. 6.2% of the world’s population lives in Eastern and Southern Africa. Like other countries, Ethiopia also adopted the Joint United Nations Program on HIV/AIDS (UNAIDS) fast track strategy of 90-90-90.3 However, of all people living with HIV, 79% knew their status, 62% were on treatment, and 53% were virally suppressed in 2018.4,5 Moreover, patients who are not retained due to loss to follow–up are likely to develop a high viral load, which increases the risk of infecting others.6,7 Countries face the dual challenge of managing and sustaining growing cohorts of patients on ART in addition to the need for increasing access to ART for the patients who still do not have access to it. The high levels of attrition undermine the proven benefits of early treatment for individuals and the prevention of onward transmission of HIV.8 Patient adherence to the treatment and attrition from care emerged as a serious public health concern to gain the desired outcome of a combined ART treatment regimen.9 Lost to follow-up or attrition from care negatively impacts the immunological benefits of ART, which leads to drug resistance, treatment failure, morbidity, hospitalization, and death.8,10–12 Despite the implementation of free highly active antiretroviral treatment, decentralization, role shifting of ART programs, appointment spacing model, fixed–dose combinations, patient monitoring, and involvement of case managers and adherence supporters significantly increased HIV/AIDS infected people’s retention, reducing morbidity and mortality through viral load suppression and improved adherence.13–18 However, almost half of all HIV patients have undetected viral loads, and as a result, the number of people who are lost to follow-up is higher than the number of people who start new care.19 The extent of non-retention of treatment and the factors that contribute to it can differ from one location to the next. It will be crucial to evaluate the magnitude and factors of attrition among people living with HIV/AIDS in order to establish successful intervention strategies and enhance their quality of life. Furthermore, the impact of new HIV/AIDS initiatives such as viral load status, ASM, and a test-and-treat approach was not considered in previous studies. As a result, further research was done to evaluate the rate of attrition and its predictors among adults on antiretroviral therapy.

Methods

Study Design and Setting

An institution-based retrospective cohort study was conducted in Woldia Town Public Health Facilities. Woldia Town is located in North Wollo Zone of Amhara regional state at 520km away from Addis Ababa. In Ethiopia, ART began as a free service in 2005. Ethiopia’s Federal Ministry of Health currently recommends ART care based on the 2018 National Guideline, which was revised from the 2014 National Guideline. A differentiated service delivery system, varying from monthly to six-month intervals, is recommended by the latest national guideline. The town report in January 2020 showed that more than 5,700 were taking ART and more than 5,570 of them were adults. The data were collected from February 1, 2020, to March 30, 2020.

Study Populations, Sample Size and Sampling Procedure

All HIV-infected patients who had ever begun antiretroviral therapy (ART) and were 15 years old or older at the time of ART initiation in Woldia Town Public Health Facilities were included in the study. The research included HIV-positive adults who had begun antiretroviral therapy (ART) in Woldia General Hospital and Woldia Health Center between February 2014 and January 2020. The sample size was estimated using Epi Info 7.2 Stat-Calc software and using some independent variables based on the following assumptions: degree of confidence=95%, power=80%, exposed: unexposed ratio=1:1. So, a larger sample size of the minimum sample of the current study was 634. In terms of the sampling process, ART data were first exported from SMART Care to Microsoft Excel, and then study participants were chosen using a simple random sampling procedure using lottery methods based on their medical record numbers. Figure 1
Figure 1

Profiles of HIV/AIDS clients in Woldia Town Public Health Facilities (February 1, 2014 to January 31, 2020) Northeast Ethiopia; 2020.

Profiles of HIV/AIDS clients in Woldia Town Public Health Facilities (February 1, 2014 to January 31, 2020) Northeast Ethiopia; 2020.

Data Collection Tool, Methods and Measurements

The data abstraction tool was adapted from the ART intake form, register, and follow-up form. The clients’ outcome status was determined based on the ART register, SMART care, and patient follow-up card. It was recorded as dead (of any cause), lost and dropped, stopped, or retained in care. The study began when clients’ initiated ART; then, the duration of the study was the follow-up of clients to the next visit. Adult clients who were transferred out (TO) and a patient chart with missed age and date of ART initiation were excluded. The time component was taken first date of ART initiation, which was considered as a baseline date or time zero for this study. The event of interest considered as success (event = 1) if adult ART clients and (event = 0) otherwise. The outcome was labeled as lost, dead, stop, or retained. The follow-up status of clients was calculated in months and a maximum of 72 months or 6 years. If the client was active on follow-up during the data collection period, then the client was labeled as retained in care otherwise labeled as censored due to administrative censoring otherwise labeled as attrition from cares. The time to attrition or censoring was recorded in months starting from the date of ART initiation to the last date of a missed appointment, stop or death, and the last date of medication pick up in case of administrative censoring.

Data Quality Management

As a quality control measure, sampled data from the charts to be chosen was re-abstracted. The data quality was reviewed by ensuring its completeness, monitoring data collectors on a continuous basis, and keeping a close eye on data management.

Data Processing and Analysis

The primary outcome variable was attrition from care. The data were entered into Epi-Data version 3.1 and exported to STATA 14.1 for further analysis. Cox proportional hazard model assumption was checked using graphical representation (log-log plot or Kaplan–Meier and predicted survival plot), the goodness of fit like Scaled Schoenfeld residuals for each variable, Schoenfeld residuals for the global test and lastly, time vary covariates. To identify predictors of attrition Proportional Hazard Cox regression model was fitted. A significant difference in survival curves was tested by equality of survival functions using a Log rank test. The survival and hazard probability of the risk group were shown by the survival graph and the hazard failure estimated curve, respectively. All Variables were assessed with the outcome variables in the bi-variable analysis at P-value ≤0.25 were included in the multivariable Cox Proportional Hazard Model. An adjusted hazard ratio with their corresponding 95% confidence interval was presented and variables with a P-value less than 0.05 were also considered statistically significant.

Ethics Consideration

The Ethical Review Committee of the College of Medicine and Health Sciences, Wollo University had secured the ethical clearance letter. The school of public health also offered an official letter to all health facilities of the study area. The data collection was conducted following the Helsinki Declaration and confidentiality was maintained anonymously. Informed consent of the participants to review their chart was waived by the Quality Assurance Committee of the respective Health Facilities on behalf of their clients.

Result

Sociodemographic and Behavioral Characteristics

Totally, 634 patients who had a follow-up at ART clinics in public health facilities were included in the study. The mean ages of the respondents were 35.9 (SD±11.148) years. The median duration of months on ART from the start of ART till the end of follow-up period was 32 months (IQR 15−55). Of the total respondents, 345 (54.4%) of them were females, and 354 (55.8%) were urban dwellers. The majority of the respondents, 518 (81.7%), were Orthodox Christian followers, and 271 (42.7%) of them were unable to read and write. Two hundred sixty-three (41.5%) of the respondents were unemployed, and 310 (48.9%) of them were married. Three-fourth of respondents, 470 (74.1%), were disclosed to someone else, and regarding medication adherence 413 (65.1%) of them were with good adherence at the last visit of patient follow-up. Eighty-eight (13.9%) of the respondents were substance users in addition to their ART medication. Table 1
Table 1

Sociodemographic and Behavioral Characteristic of Adults Receiving ART Related with Attrition in Woldia Town Public Health Facilities, Northeast Ethiopia 2020, n=634

VariablesCategoriesTotal (%)
Sex of respondentFemale345 (54.4)
Male289 (45.6)
Age of respondent15–24 years80 (12.6)
25–34 years248 (39.1)
35–44 years172 (27.1)
≥45 years134 (21.1)
Residence of clientUrban354 (55.8)
Rural280 (44.2)
ReligionOrthodox Christian518 (81.7)
Muslim116 (18.3)
Educational statusUnable to read and write271 (42.7)
Primary201 (31.7)
Secondary & above162 (25.6)
Occupational statusEmployed a121 (19.1)
Farmer b250 (39.4)
Unemployed c263 (41.5)
Marital statusNever married130 (20.5)
Married310 (48.9)
Others d194 (30.6)
Disclosure statusYes470 (74.1)
No164 (24.9)
Adherence levelGood413 (65.1)
Fair139 (21.9)
Poor82 (12.9)
Substance useYes88 (13.9)
No546 (86.1)

Notes: aPrivate sector servant, civil servant and merchant; bFarmer and house wife; cStudent, daily laborer and unemployed; dDivorced, separated and widowed.

Sociodemographic and Behavioral Characteristic of Adults Receiving ART Related with Attrition in Woldia Town Public Health Facilities, Northeast Ethiopia 2020, n=634 Notes: aPrivate sector servant, civil servant and merchant; bFarmer and house wife; cStudent, daily laborer and unemployed; dDivorced, separated and widowed.

Baseline Clinical and Health System Factors

Out of the total respondents, 264 (41.6%) were linked to ART care from VCT, and 206 (32.5%) of them were underweight (<18.5 kg/m2) according to their BMI. Three-fourth (75.1%) of the patients started ART at working functional status and 195 (30.8%) at advanced WHO stage of either stage III or IV. Table 2
Table 2

Baseline Clinical and Health System Characteristics Among Adult Clients Who Were Receiving ART in Woldia Town Public Health Facilities, 2020, (n=634)

VariablesCategoryTotal (%)
ART linkage pointaVCT*264 (41.6)
OPD/IPD*205 (32.3)
MCH/Othersa165 (26.0)
Year of ART initiation2014–2016329 (51.9)
2017–2018227 (35.8)
2019–202078 (12.3)
BMI<18.5 kg/m2206 (32.5)
≥18.5 kg/m2428 (67.5)
Functional statusWorking476 (75.1)
Ambulatory104 (16.4)
Bedridden54 (8.5)
WHO clinical stageStage I252 (39.7)
Stage II187 (29.5)
Stage III152 (24.0)
Stage IV43 (6.8)
TB treatment at baselineYes69 (10.9)
No565 (89.1)
IPT* treatment at baselineYes313 (49.4)
No321 (50.6)
Baseline CD4 countNot recorded134 (21.1)
≤350306 (48.3)
>350194 (30.6)
VL* count at ≥ 6 month≤1000425 (67.0)
>1000/no record209 (33.0)
Baseline HemoglobinNot recorded324 (51.1)
≤1059 (9.3)
>10251 (39.6)
Cotrimoxazole Preventive Therapy (CPT) at baselineYes372 (58.7)
No262 (41.3)
NRTI at baselineTDF containing586 (92.4)
AZT/ABC containing48 (7.6)
NNRTI/INSTI* at baselineDTG49 (7.7)
EFV531 (83.8)
NVP54 (8.5)
OI* presenceYes132 (20.8)
No502 (79.2)
Mental illnessYes36 (5.7)
No/no record598 (94.3)
Client is on ASM*Yes159 (25.1)
No475 (74.9)
Drug side effect/toxicityYes79 (12.5)
No555 (87.5)

Note: aClients linked to ART other than VCT, OPD, IPD like MCH, youth-friendly service.

Abbreviations: *INSTI, integrase strand transfer inhibitor (also known as integrase inhibitors); *IPT, isoniazid preventive therapy, VL*, viral load; OI*, opportunistic infection ASM*, appointment spacing modeling; VCT*, voluntary counseling and testing; OPD*, out patient; IPD*, in patient department; MCH*, maternal and child health.

Baseline Clinical and Health System Characteristics Among Adult Clients Who Were Receiving ART in Woldia Town Public Health Facilities, 2020, (n=634) Note: aClients linked to ART other than VCT, OPD, IPD like MCH, youth-friendly service. Abbreviations: *INSTI, integrase strand transfer inhibitor (also known as integrase inhibitors); *IPT, isoniazid preventive therapy, VL*, viral load; OI*, opportunistic infection ASM*, appointment spacing modeling; VCT*, voluntary counseling and testing; OPD*, out patient; IPD*, in patient department; MCH*, maternal and child health.

Attrition Among Adult Patients Receiving Antiretroviral Therapy

At the end of six years, 483 (76.2%) of respondents had been retained, while 91 (14.3%) had died, 57 (9.0%) had LTFU, and 3 (0.5%) had stopped. The Kaplan-Meier estimate of attrition from care were 9.6% (7.6–12.2), 13.6% (11.2–16.6), 16.3% (13.6–19.5), 18.3% (15.4–21.6), 23.7% (20.3–27.5), 27.1% (23.4–31.3), 29.2% (25.2–33.8) and 31.8% (27.0–37.1) at 6 months, 1 year, 18 months, 2nd year, 3rd year, 4th year, 5th year and 6th year, respectively, while the retention in care was vice versa. Figure 2
Figure 2

Kaplan–Meier failure estimates by failure function of attrition among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020.

Kaplan–Meier failure estimates by failure function of attrition among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020.

Incidence of Attrition

The total time observed was found to be 1807.08 person-years of observation with a median follow-up time of 2.67 years (IQR 1.25−4.67). The overall incidence rate of attrition was estimated to be 8.36 (95% CI: 7.12−9.80) per 100 person-years (PY). Of the total incidence of attrition rate, 5.04/100 PY, 3.15/100 PY, and 0.17/100 PY attributed to death, LTFU and stop ART, respectively. The incidence of attrition had shown that differences among different levels of the WHO clinical stage. The incidence of attrition at advanced WHO clinical stage of either stage III or IV was higher than stage one (Figure 3).
Figure 3

Kaplan–Meier failure estimates of attrition by baseline WHO stage among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020.

Kaplan–Meier failure estimates of attrition by baseline WHO stage among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020. The incidence of attrition has also shown differences among different levels of adherence. The incidence of attrition among respondents with sub-optimal adherence status of fair or poor was higher than respondents with good adherence (Figure 4).
Figure 4

Kaplan–Meier failure estimates of attrition by adherence level among adult patients on ART in Woldia Town Public Health Facilities, Northeast Ethiopia, 2020.

Kaplan–Meier failure estimates of attrition by adherence level among adult patients on ART in Woldia Town Public Health Facilities, Northeast Ethiopia, 2020.

Predictors of Attrition Among Adult ART Clients

On bivariate cox regression sex, age of respondent, year of enrollment to HIV care, BMI, functional status, baseline WHO stage, co-infection with TB at baseline, viral load count, history of CPT prophylaxis, IPT treatment, presence of at least one OI, mental illness, substance abuse, history of disclosure, adherence level and ASM were found to be associated with attrition at P value of 0.25 or lower. After conducting a bi-variable analysis, the final model was fitted using a back ward multivariable cox–regression model. Finally, seven of the predictors were found to have statistically significant with attrition during multivariable cox proportional regression analysis at 95% confidence level. The study indicated that age of respondent was found to be significant predictor of attrition, in which the risk of attrition among young adults (15−24 years) was 2 times higher as compared to older adults (25–34 years) (AHR=2.0, 95% CI, 1.11−3.58). Respondents with recent year of enrollment had 2.3 times more likely to undergo attrition as compared to previous year of enrolment (AHR=2.32, 95% CI, 1.08–5.01). Participants who were with bedridden functional status had 3 times more risk of attrition as compared to working functional status (AHR=3.25, 95% CI, 1.33−7.96). The risk of attrition among those with advanced WHO stage was higher as compared to early stage, in which the risk of attrition among those on stage III was 3.6 (AHR=3.57, 95% CI, 1.58−8.06) and among stage IV was 5.5 (AHR=5.46, 95% CI, 1.97−15.13) times higher as compared to those on WHO stage one. The risk of attrition among those with viral load result of ≤1000 copies/mL lowers the risk of attrition by 0.11 (AHR=0.11, 95% CI, 0.06−0.23) times as compared to those with >1000 copies/mL. Disclosure status was found to have statistically significant association with attrition, in which the risk of attrition among those who had not disclosed their HIV status was 2 (AHR=2.03, 95% CI, 1.22−3.37) times higher as compared to those who had disclosed their status to anyone else. The risk of attrition among those with fair/poor adherence was higher as compared to those having good adherence, in which the risk of attrition among those who had fair adherence was 1.9 (AHR=1.86, 95% CI, 1.01−3.43) and poor adherence was 3.2 (AHR=3.19, 95CI, 1.67−6.09) times higher as compared to those having good adherence level. Table 3
Table 3

Predictors of Attrition Among Patients with HIV/AIDS Receiving ART in Woldia Town Public Health Facilities, January 2020

PredictorsCensored (%)Attrition (%)Crude HR 95% CIAdjusted HR95% CI
Age of respondent
 15−2449 (7.7)31 (4.9)2.82 (1.69−4.70)2.0 (1.11−3.58)**
 25−34209 (33.0)39 (6.2)1.01 (0.62− 1.64)0.72 (0.42−1.24)
 35−44144 (22.7)28 (4.4)1.0001.000
 ≥4581 (12.8)53 (8.3)2.87 (1.82−4.55)1.45 (0.84−2.49)
Year of enrolment
 2014−2016244 (38.4)85 (13.4)1.0001.000
 2017−2018176 (27.8)51 (8.0)1.35 (0.94–1.96)1.50 (0.96−2.37)
 2019−2020a63 (9.9)15 (2.4)1.93 (1.08–3.44)2.32 (1.08–5.01)**
BMI in kg/m2
 <18.5114 (18.1)92 (14.5)4.03 (2.90−5.60)0.91 (0.55–1.49)
 ≥18.5369 (58.2)59 (9.3)1.0001.000
Functional status
 Working432 (68.1)44 (6.9)1.0001.000
 Ambulatory45 (7.1)59 (9.3)8.94 (6.03−13.24)1.46 (0.80−2.67)
 Bedridden6 (0.9)48 (7.6)28.16 (18.24–43.48)3.25 (1.33−7.96)**
WHO stage
 Stage I241 (38.0)11 (1.7)1.0001.000
 Stage II157 (24.8)30 (4.7)3.59 (1.80−7.16)1.75 (0.82−3.71)
 Stage III78 (12.3)74 (11.7)15.83 (8.39−29.86)3.57 (1.58−8.06)***
 Stage IV7 (1.1)36 (5.7)45.81 (23.12−90.74)5.46 (1.97−15.13)***
Baseline TB Rx
 Yes31 (4.9)38 (6.0)3.70 (2.56−5.36)0.70 (0.48−1.13)
 No452 (71.3)113 (17.8)1.0001.000
IPT Rx at baseline
 Yes291 (46.0)22 (3.3)6.72 (4.27–10.56)1.68 (0.99–2.86)
 No192 (30.3)129 (20.3)1.0001.000
Viral load count
 ≤1000407 (64.2)18 (2.7)0.03 (0.02–0.05)0.11 (0.06−0.23)***
 >100076 (12.0)133 (21.0)1.0001.000
Presence of OI
 Yes60 (9.5)72 (11.3)5.26 (3.81−7.27)1.19 (0.71−1.97)
 No423 (66.7)79 (12.5)1.0001.000
Disclosure status
 Yes429 (67.7)41 (6.4)1.0001.000
 No54 (8.5)110 (17.4)12.20 (8.49−17.55)2.03 (1.22−3.37)***
Adherence label
 Good389 (61.4)24 (3.7)1.0001.000
 Fair73 (11.5)66 (10.4)10.23 (6.41− 16.34)1.86 (1.01−3.43)**
 Poor21 (3.3)61 (9.6)24.72 (15.30−39.93)3.19 (1.67−6.09)***
ASM
 Yes152 (24.0)7 (1.1)1.0001.000
 No331 (52.3)144 (22.6)9.40 (4.40−20.11)1.28 (0.54–3.06)

Notes: **p<0.05 at multivariate analysis; ***p<0.001 at multivariate analysis; Model fitness was checked using global test for proportional hazard assumption, the P value was 0.355 and the model was fitted; a2019–2020, recent calendar year is patients who were initiated ART drug in 2019 till the end of study periods.

Predictors of Attrition Among Patients with HIV/AIDS Receiving ART in Woldia Town Public Health Facilities, January 2020 Notes: **p<0.05 at multivariate analysis; ***p<0.001 at multivariate analysis; Model fitness was checked using global test for proportional hazard assumption, the P value was 0.355 and the model was fitted; a2019–2020, recent calendar year is patients who were initiated ART drug in 2019 till the end of study periods.

Discussion

The overall incidence of attrition was 8.36/100 PY. This finding was lower as compared to studies conducted in Kenya (23.1/100 PY), Sub–Saharan Africa (14.2/100 PY), South Africa (26.4/100 PY) and India (14.1/100PY).20–23 This might be due to the practice of ASM implementation in the current study compared with the previous one, which was conducted before WHO recommendations of the ASM model24 and ongoing active tracing of clients who had missed their appointment by case managers and adherence supporters. The incidence of attrition was higher than the studies conducted in Ethiopia (6.5/100PY)25 and in Mozambique (2.2/100 PY).26 This high attrition rate might be due to the rapid scale–up of ART services without considering the package of care to the clients7 and the absence of practicing community ART services.26 Findings from this study revealed that young age (15–24) increases the hazard of attrition by 2 times as compared to 35–44 years of adults. This finding was in line with studies conducted in Kenya and Mozambique.20,27 This high hazard of attrition might be due to high loss to follow–up as a result of fear related to stigma and discrimination in addition to low psychosocial support during a health facility visit to pick up ART medication.28 Adopting innovative approaches like the provision of community ART services and creating youth-friendly services might reduce a high attrition rate, which was supported by studies conducted in Mozambique and systematic review including Sub Saharan Africa.26,27,29 In this study, initiation in recent calendar years increases the hazard of attrition by 2.32 times as compared to individuals who started ART in the previous calendar years. This finding adds consistent evidence with studies in Côte d’Ivoire, Zimbabwe, Rwanda.30–33 However, this finding was in contrast with previous studies conducted in Ethiopia, which prevents hazard of attrition by 33%,11 Haiti reduced the hazard of attrition by 63%,34 Latin America and the Caribbean reduced by 41%35 when clients were initiated ART in recent calendar years. The possible explanation behind this high attrition was high lost follow-up due to the shift of Ethiopian national ART guideline from <500 CD4 cells to test and treat and silent referral of clients towards nearby health facilities as a result of the decentralization of HIV care as well as inadequate adherence of clients at the time of ART initiation.36 Findings from this study revealed that bedridden functional status at baseline increases the hazard of attrition by 3.25 times as compared to working functional status. This finding was in line with previous studies conducted in Ethiopia,37–39 Zimbabwe, Tanzania, Uganda and Zambia.32,40,41 In this study, advanced WHO stage III and stage IV at baseline increases the hazard of attrition by 3.57 and 5.46 times, respectively, as compared to stage I. This finding was in line with studies in Eswanti, Zimbabwe, Rwanda42–44 and Myanmar.45 The possible explanation behind this would be late enrolment of individuals towards HIV care at advanced stages (stage III and IV) and referral of complicated cases to the hospital, which leads to a higher risk of mortality.33,46–48 An interesting finding from this study revealed that recorded viral load result of ≤1000 copies/mL prevented the hazard of attrition by 89% as compared to >1000 copies/mL. Viral load measurement is an indicator of successful medication adherence to clients and a suppressed viral load result is less risk of attrition.49 This finding implies the need for expansion to viral load testing sites to attain universal access to timely viral load monitoring to avoid premature switching of clients to either second- or third-line ART regimen, which is more toxic and not as effective as the first-line regimen. The study found that individuals who had not disclosed their status to anyone were prone to the hazard of attrition by 2 times as compared to those who had disclosed their status. This result was consistent with studies conducted in Ethiopia,50 Democratic Republic of Congo51 and England.52 The possible explanation behind this result might be due to fear of using ARV medication in social places as well as forgetting to take it timely. This results from a lack of social support to collect and to take the medication regularly. This finding emphasizes applying weekly mobile phone text messages to avoid missing appointment dates, especially for clients who had not disclosed their status.53 The study showed that inadequate adherence level of fair/poor increased the hazard of attrition by 1.86 and 3.19 times, respectively. This finding was in line with studies conducted in Ethiopia,54 Nigeria and Côte d’Ivoire’.12,30 This was due to non-adherence clients have discontinued their lifelong ART treatment due to poor drug and clinical adherence, which resulted in high viral load, treatment failure, easy probability of contracting OIs, and then they would have died. Furthermore, this high hazard of attrition might be due to substance use55 and suboptimal screening of individuals with HIV for mental health as a result of the fact that mental illnesses are prevalent among clients with HIV/AIDs, which leads to forgetting to take medication timely.38 This finding implied the need for mental health integration with ART services, which leads to improving attrition for achieving the second and third 90 of UNAIDs fast–track strategy of Ethiopia. As it was secondary data analysis, the incompleteness of records was the challenge to undergo in this study.

Limitation of the Study

This study is not without limitation since it includes only patients’ medical records with complete data, so this might have made a selection bias and also shares the limitations of retrospective studies.

Conclusion

The result of this study showed that the incidence of attrition among adults receiving antiretroviral therapy was high. However, as a standard, every client who started antiretroviral therapy should be retained. The main positive predictors of attrition were Young age (15–24), recent year of ART initiation, baseline functional status, advanced WHO stage (III &IV), no disclosure status, fair/poor adherence while suppressed viral load result (≤1000 copy/mL) had a preventive effect on attrition.
  46 in total

1.  The Role of Early HIV Status Disclosure in Retention in HIV Care.

Authors:  Latesha Elopre; Edward W Hook; Andrew O Westfall; Anne Zinski; Michael J Mugavero; Janet Turan; Nicholas Van Wagoner
Journal:  AIDS Patient Care STDS       Date:  2015-11-20       Impact factor: 5.078

2.  Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities.

Authors:  Yibeltal Assefa; Abiyou Kiflie; Dessalegn Tesfaye; Damen Haile Mariam; Helmut Kloos; Wouters Edwin; Marie Laga; Wim Van Damme
Journal:  BMC Health Serv Res       Date:  2011-04-18       Impact factor: 2.655

3.  High loss to followup and early mortality create substantial reduction in patient retention at antiretroviral treatment program in north-west ethiopia.

Authors:  Mamo Wubshet; Yemane Berhane; Alemayehu Worku; Yigzaw Kebede; Ermias Diro
Journal:  ISRN AIDS       Date:  2012-06-14

4.  Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.

Authors:  Gerardo Alvarez-Uria; Praveen K Naik; Raghavakalyan Pakam; Manoranjan Midde
Journal:  Glob Health Action       Date:  2013-09-12       Impact factor: 2.640

5.  Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003-2015.

Authors:  Hailay Abrha Gesesew; Paul Ward; Kifle Woldemichael; Lillian Mwanri
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

6.  Determinants to antiretroviral treatment non-adherence among adult HIV/AIDS patients in northern Ethiopia.

Authors:  Berhe Beyene Gebrezgabher; Yigzaw Kebede; Melaku Kindie; Desalegn Tetemke; Mebrahtu Abay; Yalemzewod Assefa Gelaw
Journal:  AIDS Res Ther       Date:  2017-03-21       Impact factor: 2.250

7.  Body and mind: retention in antiretroviral treatment care is improved by mental health training of care providers in Ethiopia.

Authors:  Tezera Moshago Berheto; Sven Gudmund Hinderaker; Mbazi Senkoro; Hannock Tweya; Tekalign Deressa; Yimam Getaneh; Gulilat Gezahegn
Journal:  BMC Public Health       Date:  2018-07-20       Impact factor: 3.295

8.  Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015.

Authors:  Richard Makurumidze; Tsitsi Mutasa-Apollo; Tom Decroo; Regis C Choto; Kudakwashe C Takarinda; Janet Dzangare; Lutgarde Lynen; Wim Van Damme; James Hakim; Tapuwa Magure; Owen Mugurungi; Simbarashe Rusakaniko
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

9.  The association between self-reported stigma and loss-to-follow up in treatment eligible HIV positive adults in rural Kwazulu-Natal, South Africa.

Authors:  Michael Evangeli; Marie-Louise Newell; Linda Richter; Nuala McGrath
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

Review 10.  Mortality and Its Predictors among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Systematic Review.

Authors:  Mohammed Biset Ayalew
Journal:  AIDS Res Treat       Date:  2017-10-30
View more
  4 in total

1.  Predictors of Loss to Follow-Up among HIV-Infected Adults after Initiation of the First-Line Antiretroviral Therapy at Arba Minch General Hospital, Southern Ethiopia: A 5-Year Retrospective Cohort Study.

Authors:  Mathewos Alemu Gebremichael; Mekdes Kondale Gurara; Haymanot Nigussie Weldehawaryat; Melkamu Merid Mengesha; Dessalegn Ajema Berbada
Journal:  Biomed Res Int       Date:  2021-11-11       Impact factor: 3.411

2.  Incidence and predictors of attrition among children on antiretroviral therapy at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: Retrospective follow-up study.

Authors:  Ermias Sisay Chanie; Debrework Tesgera Beshah; Amare Demsie Ayele
Journal:  SAGE Open Med       Date:  2022-02-11

3.  Attrition and associated factors among children living with HIV at a tertiary hospital in Eritrea: a retrospective cohort analysis.

Authors:  Samuel Tekle Mengistu; Ghirmay Ghebrekidan Ghebremeskel; Aron Rezene; Mahmud Mohammed Idris; Tsegereda Gebrehiwot Tikue; Mohammed Elfatih Hamida; Oliver Okoth Achila
Journal:  BMJ Paediatr Open       Date:  2022-07

4.  Development and validation of a risk prediction model for lost to follow-up among adults on active antiretroviral therapy in Ethiopia: a retrospective follow-up study.

Authors:  Dawit Tefera Fentie; Getahun Molla Kassa; Sofonyas Abebaw Tiruneh; Achenef Asmamaw Muche
Journal:  BMC Infect Dis       Date:  2022-09-07       Impact factor: 3.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.